Sanofi announced a €400 million (approximately $475 million) investment over five years to create a unique vaccine production center in Singapore. This facility will be made with the intention to push the boundaries of operations through new manufacturing and digital technologies. In partnership with the Singapore Economic Development Board, the new site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America.
This announcement follows a $925 million investment in a Toronto flu vaccine facility, which is part of a larger company growth strategy involving vaccine manufacturing.
According to the French drugmaker, this investment furthers its commitment to driving the future of vaccines by expanding manufacturing capabilities to ensure quality and scale, while responding to the risk of future pandemics. The project is expected to create up to 200 local jobs.
This factory will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines simultaneously. The factory will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types.
The project is currently entering its design phase with construction expected to begin in Q3 2021. The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed.
Read the Sanofi statement